Abrams Capital's $4.64B Bet: LOAR, Auto, and Tech

David Abrams' Abrams Capital Management reported an equity portfolio valued at roughly $4.64 billion for the latest quarter, a snapshot of a highly concentrated, long-term value strategy. The filing reveals a portfolio where the top 10 holdings absorb nearly all assets, with LOAR Holdings alone commanding almost 40% of the total. Activity was minimal, with only a few notable adjustments to long-standing positions.

The simple read is that Abrams is doubling down on a few high-conviction bets. The better market read is that this portfolio structure itself is a signal: Abrams is willing to accept extreme single-name risk when he believes the margin of safety is wide enough. For traders tracking 13F filings, the concentration ratio matters more than any single buy or sell. A portfolio where the largest position is 40% of assets is not diversified. It is a statement that the manager expects LOAR to compound capital at a rate that justifies the lack of diversification.

LOAR Holdings: The 40% Anchor

LOAR Holdings (ticker not provided in source) represents the core of the Abrams thesis at $1.84 billion, or 39.59% of the portfolio. This is not a small tactical bet. It is a portfolio-defining position that will drive the fund's absolute returns more than any other single factor.

What This Means for the Portfolio

A single position of this size means that a 20% decline in LOAR would wipe out roughly 8% of the total portfolio value. Conversely, a 20% gain would add nearly the same amount. Abrams is effectively telling the market that he has done the work and believes the downside is limited and the upside is substantial. The rest of the portfolio is structured around this core bet.

Auto and Consumer Exposure: Lithia, Asbury, Tempur Sealy, U-Haul

The portfolio carries heavy exposure to automotive and consumer cyclical businesses. Lithia Motors (LAD) at $622 million (13.41%), Asbury Automotive Group (ABG) at $421.2 million (9.08%), Tempur Sealy International (TPX) at $428.6 million (9.24%), and U-Haul Holding (UHAL.B) at $145.2 million (3.13%) collectively represent nearly 35% of assets.

The Mechanism: Durable Demand vs. Macro Risk

Abrams is betting that these businesses have pricing power and operational leverage that will protect earnings even if the economy slows. Lithia Motors and Asbury Automotive are auto retailers that benefit from a constrained supply of used cars and a steady stream of service revenue. Tempur Sealy is a mattress manufacturer with brand strength and a history of margin expansion. U-Haul is a self-storage and truck rental business with a moat in its distribution network.

The risk is that a recession would hit consumer discretionary spending hard. Auto sales and big-ticket home goods are typically among the first categories consumers cut. Abrams appears to be betting that the current consumer is more resilient than the consensus expects, or that these companies have restructured their cost bases enough to weather a downturn.

Tech Exposure: Alphabet and Meta

Technology exposure is limited to two platform businesses: Alphabet Class A (GOOGL) at $536.5 million (11.57%) and Meta Platforms (META) at $186 million (4.01%). Both generate enormous free cash flow and dominate their respective advertising markets.

Why These Two?

Abrams is not buying speculative tech. He is buying cash-generating monopolies in digital advertising. Alphabet and Meta control the two largest ad platforms in the world, and both are investing heavily in AI infrastructure. The thesis is straightforward: these businesses will continue to grow earnings at a mid-to-high single-digit rate for years, and the current valuations do not fully reflect that durability.

The modest reduction in Alphabet shares (down 50,862 shares, or 2.65%) is routine portfolio management. It does not signal a change in conviction. The position remains one of the top three holdings.

What Was Sold: Energy Transfer and Nuvation Bio

Two positions saw significant changes. Energy Transfer was fully exited. The position had represented about 1.78% of the portfolio. The exit could reflect valuation discipline after a run-up in energy infrastructure stocks, or a reallocation of capital into higher-conviction ideas like LOAR.

Nuvation Bio (NUVB) shares were cut by 2.54 million shares, a 66.67% reduction. This is a material trim. Nuvation is a biotech company with no approved products and a history of clinical-stage volatility. The reduction could reflect risk management after a price move, or a reassessment of the pipeline's probability of success. The remaining position is tiny at $5.4 million (0.12%), suggesting Abrams is keeping a small toehold for optionality.

Portfolio Structure: The AlphaScala Lens

AlphaScala data: GOOGL carries an Alpha Score of 65/100 (Moderate) at $380.34, down 2.51% on the day. META scores 65/100 (Moderate) at $632.51, down 0.44%. CPNG scores 28/100 (Weak). These scores suggest that the market is pricing in moderate risk for the tech names but sees weakness in Coupang's setup.

What Confirms or Weakens the Thesis

For traders watching this portfolio, the key question is whether Abrams' conviction in LOAR is justified. The stock is not widely covered, and the lack of analyst attention means that any negative news could hit the stock hard. A quarterly earnings miss or a change in the company's capital allocation strategy would be the biggest risk.

For the auto and consumer positions, watch same-store sales and inventory levels. If Lithia Motors or Asbury Automotive report falling new car sales or rising used car inventory, the thesis of durable demand weakens. If Tempur Sealy reports margin compression from raw material costs, the margin-of-safety argument erodes.

For Alphabet and Meta, the key metric is ad revenue growth. Both companies are investing heavily in AI, and the market is watching for a return on that capital. If ad growth slows, the stocks will reprice.

The Final Takeaway

Abrams Capital's portfolio is a study in concentrated value investing. The manager is willing to accept extreme single-stock risk in LOAR, layer in cyclical exposure through auto and consumer names, and add stability through cash-generating tech platforms. The limited turnover and small number of adjustments suggest a patient approach. The full exit from Energy Transfer and the large trim in Nuvation Bio show that Abrams is not afraid to cut positions when the thesis changes.

For traders, this filing is a useful reference point for understanding how a disciplined value manager allocates capital in the current environment. The portfolio is not a recommendation to buy any of these names. It is a map of one investor's conviction. The real question is whether that conviction is right.